GILD
A quarter that didn’t just survive — it flexed
Gilead opened 2026 with a pretty solid flex: the company said its first-quarter results showed 8% year-over-year growth in the base business and 10% growth in HIV. That kind of combo matters because Gilead’s story has long leaned on HIV, and when that engine keeps humming, investors tend to stop worrying so much about the rest of the car.
Yeztugo is doing some heavy lifting
Management also pointed to the successful launch of Yeztugo, which helped support the growth picture. That’s important because new launches are where pharma companies either start looking like a future growth story or a very expensive museum of old blockbusters.
The real headline: guidance got a bump
The most investor-relevant line here is that Gilead raised its full-year revenue guidance. When a company nudges guidance higher, it’s basically saying: “We’re not just having a nice quarter, we think the rest of the year can keep up too.”
- Base business growth: 8% year over year
- HIV growth: 10%
- Driver called out by management: Yeztugo launch
- Guidance: full-year revenue outlook raised
Big picture: if you own GILD, this is the kind of report that can keep the bull case alive — steady core growth plus a new product doing its part is a lot more comforting than hoping one drug carries the whole plot.